Antiphospholipid antibody syndrome

Current Opinion in Ophthalmology

Volumn 23, Issue 6, 2012, Pages 528-532

  Yang, Paul ^a   Kruh, Jonathan N ^a   Stephen Foster, C ^a  

^a MASSACHUSETTS EYE RESEARCH AND SURGERY INSTITUTION   (United States)

Author keywords

2 glycoprotein I; antiphospholipid antibody syndrome; retinal artery occlusion; retinal vein occlusion; thrombosis

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; AUTOANTIBODY; BETA2 GLYCOPROTEIN 1; BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; DABIGATRAN ETEXILATE; ECULIZUMAB; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LOW MOLECULAR WEIGHT HEPARIN; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; PREDNISONE; PROTHROMBIN; PROTHROMBIN ANTIBODY; RITUXIMAB; RIVAROXABAN; WARFARIN;

ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; AUTOIMMUNE DISEASE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLURRED VISION; BRANCH RETINAL ARTERY OCCLUSION; BRANCH RETINAL VEIN OCCLUSION; CENTRAL RETINA ARTERY OCCLUSION; CENTRAL RETINA VEIN OCCLUSION; CHEMOLUMINESCENCE; COMPLEMENT ACTIVATION; DRY EYE; ECLAMPSIA; ENZYME LINKED IMMUNOSORBENT ASSAY; EPISCLERITIS; FETUS DEATH; HUMAN; IMMUNOADSORPTION; INTRACELLULAR SIGNALING; IRIDOCYCLITIS; LOW DRUG DOSE; OPTIC NEURITIS; PATHOPHYSIOLOGY; PLACENTA INSUFFICIENCY; PLASMAPHERESIS; PREECLAMPSIA; PREMATURE LABOR; PRIORITY JOURNAL; RETINA HEMORRHAGE; RETINA ISCHEMIA; RETINA NEOVASCULARIZATION; RETINA VASCULITIS; RETINOPATHY; REVIEW; SCLERITIS; SCREENING; SENSITIVITY AND SPECIFICITY; SEROLOGY; SPONTANEOUS ABORTION; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; THROMBOSIS PREVENTION; TRANSITIONAL BLINDNESS; UVEITIS; VASCULITIS; VEIN THROMBOSIS; VISUAL FIELD DEFECT; VITRITIS;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; ASPIRIN; BETA 2-GLYCOPROTEIN I; HUMANS; HYDROXYCHLOROQUINE; RETINAL ARTERY OCCLUSION; RETINAL VEIN OCCLUSION; WARFARIN;

EID: 84867863093     PISSN: 10408738     EISSN: 15317021     Source Type: Journal    
DOI: 10.1097/ICU.0b013e328358b937     Document Type: Review

References (34)

1. Taraborelli M, Andreoli L, Tincani A. Much more than thrombosis and pregnancy loss: the antiphospholipid syndrome as a 'systemic disease'. Best Pract Res Clin Rheumatol 2012; 26:79-90.
2. Pengo V. Antiphospholipid Syndrome: interpretation of laboratory data. J Haemost 2011; 9:402-403.
3. Meroni PL, Borghi MO, Raschi E, Tedesco F. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol 2011; 7:330-339.
4. Agar Ç , de Groot PG, Marquart JA, Meijers JC. Evolutionary conservation of the lipopolysaccharide binding site of b2-glycoprotein I. Thromb Haemost 2011; 106:1069-1075.
5. Gropp K, Weber N, Reuter M, et al. b2-glycoprotein I, the major target in antiphospholipid syndrome, is a special human complement regulator. Blood 2011; 118:2774-2783.
6. Chamorro AJ, Marcos M, Miró n-Canelo JA, et al. Val247Leu beta2-glycoprotein-I allelic variant is associated with antiphospholipid syndrome: Systematic review and meta-analysis. Autoimmun Rev 2012. [Epub ahead of print]
7. de Laat B, van Berkel M, Urbanus RT, et al. Immune responses against domain I of b(2)-glycoprotein I are driven by conformational changes: domain I of b(2)-glycoprotein I harbors a cryptic immunogenic epitope. Arthritis Rheum 2011; 63:3960-3968.
8. de Groot PG. Mechanisms of antiphospholipid antibody formation and action. Thromb Res 2011; 127 (Suppl 3):S40-S42.
9. Poulton K, Rahman A, Giles I. Examining how antiphospholipid antibodies activate intracellular signaling pathways: a systematic review. Semin Arthritis Rheum 2012; 41:720-736.
10. Cucnik S, Kveder T, Ulcova-Gallova Z, et al. The avidity of antibeta2-glycoprotein I antibodies in patients with or without antiphospholipid syndrome: a collaborative study in the frame of the European forum on antiphospholipid antibodies. Lupus 2011; 20:1166-1171.
11. Passam FH, Giannakopoulos B, Mirarabshahi P, Krilis SA. Molecular pathophysiology of the antiphospholipid syndrome: the role of oxidative posttranslational modification of beta 2 glycoprotein I. J Thromb Haemost 2011; 9 (Suppl 1):275-282.
12. Lim W. Complement and the antiphospholipid syndrome. Curr Opin Hematol 2011; 18:361-365.
13. Breen KA, Seed P, Parmar K, et al. Complement activation in patients with isolated antiphospholipid antibodies or primary antiphospholipid syndrome. Thromb Haemost 2012; 107:423-429.
14. Utz VM, Tang J. Ocular manifestations of the antiphospholipid syndrome. Br J Ophthalmol 2011; 95:454-459.
15. Rehak M, Meier P, Bühner E, et al. Occlusion of choroidal vessels in a patient with catastrophic antiphospholipid syndrome. Acta Ophthalmol 2011; 89:595-596.
16. Grika EP, Ziakas PD, Zintzaras E, et al. Morbidity, mortality, and organ damage in patients with antiphospholipid syndrome. J Rheumatol 2012; 39:516-523.
17. Tripodi A, de Groot PG, Pengo V. Antiphospholipid syndrome: laboratory detection, mechanisms of action and treatment. J Intern Med 2011; 270: 110-122.
18. Keeling D, Mackie I, Moore GW, et al.; British Committee for Standards in Haematology. Guidelines on the investigation and management of antiphospholipid syndrome. Br J Haematol 2012 [Epub ahead of print].
19. Saponjski J, Stojanovich L, Djokovic A, et al. Systemic vascular diseases in the antiphospholipid syndrome. What is the best diagnostic choice? Autoimmun Rev 2011; 10:235-237.
20. Capozzi A, Lococo E, Grasso M, et al. Detection of antiphospholipid antibodies by automated chemiluminescence assay. J Immunol Methods 2012; 379:48-52.
21. Devreese KM, Van Hoecke F. Anticardiolipin and antib2glycoprotein-I antibody cut-off values in the diagnosis of antiphospholipid syndrome: more than calculating the in-house 99th percentiles, even for new automated assays. Thromb Res 2011; 128:598-600.
22. De Laat B, Derksen RH, Reber G, et al. An international multicentre-laboratory evaluation of a new assay to detect specifically lupus anticoagulants dependent on the presence of antibeta2-glycoprotein autoantibodies. J Thromb Haemost 2011; 9:149-153.
23. Hoxha A, Ruffatti A, Pittoni M, et al. The clinical significance of autoantibodies directed against prothrombin in primary antiphospholipid syndrome. Clin Chim Acta 2012; 413:911-913.
24. Rodriguez-Garcia JL, Bertolaccini ML, Cuadrado MJ, et al. Clinical manifestations of antiphospholipid syndrome (APS) with and without antiphospholipid antibodies (the so-called 'seronegative APS'). Ann Rheum Dis 2012; 71:242-244.
25. Barbhaiya M, Erkan D. Primary thrombosis prophylaxis in antiphospholipid antibody-positive patients: where do we stand? Curr Rheumatol Rep 2011; 13:59-69.
26. Scoble T, Wijetilleka S, Khamashta MA. Management of refractory antiphospholipid syndrome. Autoimmun Rev 2011; 10:669-673.
27. Petri M. Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients. Curr Rheumatol Rep 2011; 13:77-80.
28. Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus 2011; 20: 206-218.
29. D'Ippolito S, Marana R, Di Nicuolo F, et al. Effect of Low Molecular Weight Heparins (LMWHs) on antiphospholipid Antibodies (aPL)-mediated inhibition of endometrial angiogenesis. PLoS One 2012; 7 [Epub ahead of print].
30. Bontadi A, Ruffatti A, Marson P, et al. Plasma exchange and immunoadsorption effectively remove antiphospholipid antibodies in pregnant patients with antiphospholipid syndrome. J Clin Apher 2012. [Epub ahead of print]
31. Sciascia S, Naretto C, Rossi D, et al. Treatment-induced downregulation of antiphospholipid antibodies: effect of rituximab alone on clinical and laboratory features of antiphospholipid syndrome. Lupus 2011; 20:1106-1108.
32. Khattri S, Zandman-Goddard G, Peeva E. B-cell directed therapies in antiphospholipid antibody syndrome: new directions based on murine and human data. Autoimmun Rev 2012. [Epub ahead of print]
33. Owaidah TM, Maghrabi K, Elkarouri MA, et al. Successful treatment of a case of catastrophic antiphospholipid syndrome with autologous BMT: case report and review of literature. Bone Marrow Transplant 2011; 46:597-600.
34. Espinosa G, Berman H, Cervera R. Management of refractory cases of catastrophic antiphospholipid syndrome. Autoimmun Rev 2011; 10:664-668.